Drug Trial Radar · NCT07096843
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Aug 25, 2025
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Climb Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and tolerability of three dose regimens of budoprutug in subjects with PMN
Conditions
- Primary Membranous Nephropathy
Interventions
budoprutugDrug
Single IV dose of study product on Day 1, Day 15, Day 169 and Day 183
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 48
Locations
38 sites in 7 countries. Site status is shown where the registry gives one.
Climb Bio Investigative Site #110
Denver, Colorado · Recruiting
Climb Bio Investigative Site #105
Orlando, Florida · Recruiting
Climb Bio Investigative Site #108
Atlanta, Georgia · Recruiting
Climb Bio Investigative Site #106
Indianapolis, Indiana · Recruiting
Climb Bio Investigative Site #101
Clifton Park, New York · Recruiting
Climb Bio Investigative Site #104
Sherman, Texas · Recruiting
Climb Bio Investigative Site# 602
Buenos Aires, Argentina · Recruiting
Climb Bio Investigative Site# 603
Buenos Aires, Argentina · Recruiting
Climb Bio Investigative Site #601
CABA, Argentina · Recruiting
Climb Bio Investigative Site #604
CABA, Argentina · Recruiting
Climb Bio Investigative Site #606
Santa Fe, Argentina · Recruiting
Climb Bio Investigative Site #502
Belo Horizonte, Brazil · Recruiting
Climb Bio Investigative Site #505
Minas Gerais, Brazil · Recruiting
Climb Bio Investigative Site #506
Pernambuco, Brazil · Recruiting
Climb Bio Investigative Site #501
Porto Alegre, Brazil · Recruiting
Climb Bio Investigative Site #503
São Paulo, Brazil · Recruiting
Climb Bio Investigative Site #504
São Paulo, Brazil · Recruiting
Climb Bio Investigative Site #403
Beijing, Changping District, China · Not yet recruiting
Climb Bio Investigative Site #401
Beijing, Cheng District, China · Recruiting
Climb Bio Investigative Site #408
Shenzhen, Guangdong, China · Not yet recruiting
Climb Bio Investigative Site #402
Wuxi, Jiangsu, China · Recruiting
Climb Bio Investigative Site #405
Jinan, Shandong, China · Not yet recruiting
Climb Bio Investigative Site #409
Yantai, Shandong, China · Recruiting
Climb Bio Investigative Site #404
Yibin, Sichuan, China · Recruiting
Climb Bio Investigative Site #406
Beijing, Xicheng District, China · Recruiting
Climb Bio Investigative Site #903
Tbilisi, Georgia · Recruiting
Climb Bio Investigative Site #902
Tbilisi, Georgia · Recruiting
Climb Bio Investigative Site #901
Tbilisi, Georgia · Recruiting
Climb Bio Investigative Site #204
Taichung, Taiwan · Recruiting
Climb Bio Investigative Site# 202
Taipei, Taiwan · Recruiting
Climb Bio Investigative Site# 201
Taipei, Taiwan · Recruiting
Climb Bio Investigative Site #205
Taipei, Taiwan · Recruiting
Climb Bio Investigative Site# 203
Taipei, Taiwan · Recruiting
Climb Bio Investigative Site #803
Ivano-Frankivsk, Ukraine · Recruiting
Climb Bio Investigative Site# 801
Kyiv, Ukraine · Recruiting
Climb Bio Investigative Site #805
Kyiv, Ukraine · Recruiting
Climb Bio Investigative Site #804
Rivne, Ukraine · Recruiting
Climb Bio Investigative Site #802
Ternopil, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.